background logo image
Episode 9

Does Keto Cause Heart Disease?

Listen, Watch & Subscribe on:

Watch

Does Keto Cause Heart Disease?

Listen

About the host

Bret Scher, MD

Bret Scher, MD

Medical Director, Metabolic Mind and Baszucki Group

Bret is the host of the Metabolic Mind YouTube channel and podcast. He is a board-certified cardiologist, lipidologist, and leading expert in therapeutic uses of metabolic therapies, including ketogenic diets. Prior to joining Baszucki Group, Bret was the medical director at DietDoctor.com, an online platform promoting improving metabolic health through low-carb nutrition, where he was a content creator and medical reviewer. Earlier in his career, he worked as a cardiologist in San Diego. Bret has spent most of his 20-year career as a preventive cardiologist, helping people improve their metabolic health and preventing heart disease using low-carb nutrition and lifestyle interventions. His deep passion for educating the public about the benefits of metabolic therapies grew from his experience with the prevailing medical teaching, which frequently misrepresents nutrition science and undervalues metabolic health. Bret received an MD from The Ohio State University College of Medicine and a BS in Biology from Stanford University. He grew up in San Diego and began competing in triathlons at an early age, which helped fuel his love of health and fitness. He continues to enjoy spending time outdoors mountain biking, swimming, hiking, and playing baseball with his two boys.
Learn more about Bret

Bret Scher, MD

Medical Director, Metabolic Mind and Baszucki Group

Bret is the host of the Metabolic Mind YouTube channel and podcast. He is a board-certified cardiologist, lipidologist, and leading expert in therapeutic uses of metabolic therapies, including ketogenic diets. Prior to joining Baszucki Group, Bret was the medical director at DietDoctor.com, an online platform promoting improving metabolic health through low-carb nutrition, where he was a content creator and medical reviewer. Earlier in his career, he worked as a cardiologist in San Diego. Bret has spent most of his 20-year career as a preventive cardiologist, helping people improve their metabolic health and preventing heart disease using low-carb nutrition and lifestyle interventions. His deep passion for educating the public about the benefits of metabolic therapies grew from his experience with the prevailing medical teaching, which frequently misrepresents nutrition science and undervalues metabolic health. Bret received an MD from The Ohio State University College of Medicine and a BS in Biology from Stanford University. He grew up in San Diego and began competing in triathlons at an early age, which helped fuel his love of health and fitness. He continues to enjoy spending time outdoors mountain biking, swimming, hiking, and playing baseball with his two boys.
Learn more about Bret

Key Highlights

  • Nutritional ketosis has never been shown to increase heart attacks, strokes, or cardiovascular deaths, as no outcome trials have ever tested ketogenic diets for cardiovascular events.
  • Many studies claiming low-carb diets increase heart disease define “low carb” as 25–40% carbohydrate intake, which is far too high to induce ketosis and cannot be used to judge ketogenic diets.
  • Observational nutrition studies suffer from major flaws including poor dietary measurement, healthy user bias, and lack of metabolic context, making them unreliable for determining keto’s cardiac risk.
  • LDL cholesterol may rise for some individuals on keto, but most people see no increase on average, and cardiovascular risk must be interpreted using full metabolic and inflammatory markers, not LDL in isolation.
  • A subgroup known as lean mass hyper-responders may see large LDL increases in ketosis, and active research is ongoing to understand this physiology, but they remain the exception rather than the rule.

Transcript

Listen, Watch & Subscribe on:

You May Also Be Interested In:

Sky High LDL and No Heart Disease? Results from Dave Feldman’s New Study
Podcast

Sky High LDL and No Heart Disease? Results from Dave Feldman’s New Study

Engineer-researcher Dave Feldman walks through the lean-mass hyper-responder (LMHR) keto-CTA trial: 100 metabolically healthy keto eaters with very high LDL/ApoB had coronary CT angiograms at baseline and ~1 year. Key finding: changes in plaque (including non-calcified plaque) did not correlate with LDL or ApoB; the best predictor of progression was pre-existing plaque. Keto itself wasn’t shown to drive plaque, and saturated-fat intake and cumulative on-diet LDL exposure didn’t track with ApoB or plaque change either. Plaque did rise modestly for some—about what’s seen in treated cohorts—while a few even regressed; interpretation should be individualized with imaging (CAC/CTA) guiding care and standard therapies used when plaque is present. Limitations (e.g., no longitudinal control group) mean more studies are needed; Dave’s team is launching follow-ups and invites open, civil debate—“don’t confuse arsonists with firefighters.” Resources: CitizenScienceFoundation.org and cholesterolcodemovie.com.

Read more

Study Shocks Cardiologists: LDL Didn’t Predict Plaque
Podcast

Study Shocks Cardiologists: LDL Didn’t Predict Plaque

This episode features cardiologist Dr. Matt Budoff on a one-year CT-angiography study of lean, keto-adhering “hyper-responders” with very high LDL/ApoB. Headline finding: no clear link between higher LDL/ApoB and coronary plaque progression; instead, baseline plaque burden predicted who progressed. Some participants even showed plaque regression despite LDL >200 mg/dL, underscoring wide individual variability. Takeaway: ketogenic diets weren’t shown to accelerate heart disease; use CAC/CTA to assess plaque and treat existing atherosclerosis per standard care, independent of diet.

Learn more

Keto-CTA Study Confusion: Addressing the Misunderstandings with Dr. Budoff
Podcast

Keto-CTA Study Confusion: Addressing the Misunderstandings with Dr. Budoff

Cardiologist Dr. Matt Budoff returns to explain how coronary CT metrics—especially percent atheroma volume (PAV) and non-calcified plaque—should be interpreted in the new lean mass hyper-responder study. He clarifies that plaque did progress in some participants, but the rise was similar to treated cohorts in other trials and was not linked to keto-induced LDL or ApoB levels. The episode unpacks why relative percent changes can mislead when baseline plaque is tiny, and why calcium score/CTA help distinguish low- from higher-risk individuals. Practical takeaway: keto wasn’t shown to drive plaque; use imaging to check for atherosclerosis and treat documented plaque per standard care, independent of diet.

Learn more

Beyond LDL: New Insights into Metabolic Health and Heart Disease
Videos

Beyond LDL: New Insights into Metabolic Health and Heart Disease

In this video, board-certified cardiologist (and Metabolic Mind’s Medical Director) Dr. Bret Scher dives into the latest science of triglyceride-rich particles and their impact on metabolic health. Learn…

Learn more

Sky High LDL and No Heart Disease? Results from Dave Feldman’s New Study
Podcast

Sky High LDL and No Heart Disease? Results from Dave Feldman’s New Study

Engineer-researcher Dave Feldman walks through the lean-mass hyper-responder (LMHR) keto-CTA trial: 100 metabolically healthy keto eaters with very high LDL/ApoB had coronary CT angiograms at baseline and ~1 year. Key finding: changes in plaque (including non-calcified plaque) did not correlate with LDL or ApoB; the best predictor of progression was pre-existing plaque. Keto itself wasn’t shown to drive plaque, and saturated-fat intake and cumulative on-diet LDL exposure didn’t track with ApoB or plaque change either. Plaque did rise modestly for some—about what’s seen in treated cohorts—while a few even regressed; interpretation should be individualized with imaging (CAC/CTA) guiding care and standard therapies used when plaque is present. Limitations (e.g., no longitudinal control group) mean more studies are needed; Dave’s team is launching follow-ups and invites open, civil debate—“don’t confuse arsonists with firefighters.” Resources: CitizenScienceFoundation.org and cholesterolcodemovie.com.

Read more

Study Shocks Cardiologists: LDL Didn’t Predict Plaque
Podcast

Study Shocks Cardiologists: LDL Didn’t Predict Plaque

This episode features cardiologist Dr. Matt Budoff on a one-year CT-angiography study of lean, keto-adhering “hyper-responders” with very high LDL/ApoB. Headline finding: no clear link between higher LDL/ApoB and coronary plaque progression; instead, baseline plaque burden predicted who progressed. Some participants even showed plaque regression despite LDL >200 mg/dL, underscoring wide individual variability. Takeaway: ketogenic diets weren’t shown to accelerate heart disease; use CAC/CTA to assess plaque and treat existing atherosclerosis per standard care, independent of diet.

Learn more

Keto-CTA Study Confusion: Addressing the Misunderstandings with Dr. Budoff
Podcast

Keto-CTA Study Confusion: Addressing the Misunderstandings with Dr. Budoff

Cardiologist Dr. Matt Budoff returns to explain how coronary CT metrics—especially percent atheroma volume (PAV) and non-calcified plaque—should be interpreted in the new lean mass hyper-responder study. He clarifies that plaque did progress in some participants, but the rise was similar to treated cohorts in other trials and was not linked to keto-induced LDL or ApoB levels. The episode unpacks why relative percent changes can mislead when baseline plaque is tiny, and why calcium score/CTA help distinguish low- from higher-risk individuals. Practical takeaway: keto wasn’t shown to drive plaque; use imaging to check for atherosclerosis and treat documented plaque per standard care, independent of diet.

Learn more

Beyond LDL: New Insights into Metabolic Health and Heart Disease
Videos

Beyond LDL: New Insights into Metabolic Health and Heart Disease

In this video, board-certified cardiologist (and Metabolic Mind’s Medical Director) Dr. Bret Scher dives into the latest science of triglyceride-rich particles and their impact on metabolic health. Learn…

Learn more